229 related articles for article (PubMed ID: 31802055)
21. Florbetaben to trace amyloid-β in the Alzheimer brain by means of PET.
Barthel H; Sabri O
J Alzheimers Dis; 2011; 26 Suppl 3():117-21. PubMed ID: 21971456
[TBL] [Abstract][Full Text] [Related]
22. Association of Amyloid Positron Emission Tomography With Changes in Diagnosis and Patient Treatment in an Unselected Memory Clinic Cohort: The ABIDE Project.
de Wilde A; van der Flier WM; Pelkmans W; Bouwman F; Verwer J; Groot C; van Buchem MM; Zwan M; Ossenkoppele R; Yaqub M; Kunneman M; Smets EMA; Barkhof F; Lammertsma AA; Stephens A; van Lier E; Biessels GJ; van Berckel BN; Scheltens P
JAMA Neurol; 2018 Sep; 75(9):1062-1070. PubMed ID: 29889941
[TBL] [Abstract][Full Text] [Related]
23. Association of short-term cognitive decline and MCI-to-AD dementia conversion with CSF, MRI, amyloid- and
Ottoy J; Niemantsverdriet E; Verhaeghe J; De Roeck E; Struyfs H; Somers C; Wyffels L; Ceyssens S; Van Mossevelde S; Van den Bossche T; Van Broeckhoven C; Ribbens A; Bjerke M; Stroobants S; Engelborghs S; Staelens S
Neuroimage Clin; 2019; 22():101771. PubMed ID: 30927601
[TBL] [Abstract][Full Text] [Related]
24. Impact of beta-amyloid-specific florbetaben PET imaging on confidence in early diagnosis of Alzheimer's disease.
Schipke CG; Peters O; Heuser I; Grimmer T; Sabbagh MN; Sabri O; Hock C; Kunz M; Kuhlmann J; Reininger C; Blankenburg M
Dement Geriatr Cogn Disord; 2012; 33(6):416-22. PubMed ID: 22814208
[TBL] [Abstract][Full Text] [Related]
25. Amyloid imaging with (18)F-florbetaben in Alzheimer disease and other dementias.
Villemagne VL; Ong K; Mulligan RS; Holl G; Pejoska S; Jones G; O'Keefe G; Ackerman U; Tochon-Danguy H; Chan JG; Reininger CB; Fels L; Putz B; Rohde B; Masters CL; Rowe CC
J Nucl Med; 2011 Aug; 52(8):1210-7. PubMed ID: 21764791
[TBL] [Abstract][Full Text] [Related]
26. Longitudinal evaluation of a novel BChE PET tracer as an early
Rejc L; Gómez-Vallejo V; Joya A; Moreno O; Egimendia A; Castellnou P; Ríos-Anglada X; Cossío U; Baz Z; Passannante R; Tobalina-Larrea I; Ramos-Cabrer P; Giralt A; Sastre M; Capetillo-Zarate E; Košak U; Knez D; Gobec S; Marder M; Martin A; Llop J
Theranostics; 2021; 11(13):6542-6559. PubMed ID: 33995675
[No Abstract] [Full Text] [Related]
27. Distinct dynamic profiles of microglial activation are associated with progression of Alzheimer's disease.
Hamelin L; Lagarde J; Dorothée G; Potier MC; Corlier F; Kuhnast B; Caillé F; Dubois B; Fillon L; Chupin M; Bottlaender M; Sarazin M
Brain; 2018 Jun; 141(6):1855-1870. PubMed ID: 29608645
[TBL] [Abstract][Full Text] [Related]
28. Positron emission tomography radiopharmaceuticals for imaging brain Beta-amyloid.
Vallabhajosula S
Semin Nucl Med; 2011 Jul; 41(4):283-99. PubMed ID: 21624562
[TBL] [Abstract][Full Text] [Related]
29. Two-year follow-up of amyloid deposition in patients with Alzheimer's disease.
Engler H; Forsberg A; Almkvist O; Blomquist G; Larsson E; Savitcheva I; Wall A; Ringheim A; Långström B; Nordberg A
Brain; 2006 Nov; 129(Pt 11):2856-66. PubMed ID: 16854944
[TBL] [Abstract][Full Text] [Related]
30. Correlation of florbetaben PET imaging and the amyloid peptide Aß42 in cerebrospinal fluid.
Schipke CG; Koglin N; Bullich S; Joachim LK; Haas B; Seibyl J; Barthel H; Sabri O; Peters O
Psychiatry Res Neuroimaging; 2017 Jul; 265():98-101. PubMed ID: 28024844
[TBL] [Abstract][Full Text] [Related]
31. A comparison of the diagnostic sensitivity of MRI, CBF-SPECT, FDG-PET and cerebrospinal fluid biomarkers for detecting Alzheimer's disease in a memory clinic.
Morinaga A; Ono K; Ikeda T; Ikeda Y; Shima K; Noguchi-Shinohara M; Samuraki M; Yanase D; Yoshita M; Iwasa K; Mastunari I; Yamada M
Dement Geriatr Cogn Disord; 2010; 30(4):285-92. PubMed ID: 20861634
[TBL] [Abstract][Full Text] [Related]
32. Comparison of
Doré V; Bullich S; Rowe CC; Bourgeat P; Konate S; Sabri O; Stephens AW; Barthel H; Fripp J; Masters CL; Dinkelborg L; Salvado O; Villemagne VL; De Santi S
Alzheimers Dement; 2019 Jun; 15(6):807-816. PubMed ID: 31101517
[TBL] [Abstract][Full Text] [Related]
33. Brain metabolic patterns in patients with suspected non-Alzheimer's pathophysiology (SNAP) and Alzheimer's disease (AD): is [
Chiaravalloti A; Barbagallo G; Martorana A; Castellano AE; Ursini F; Schillaci O
Eur J Nucl Med Mol Imaging; 2019 Aug; 46(9):1796-1805. PubMed ID: 31201430
[TBL] [Abstract][Full Text] [Related]
34. Histopathology and Florbetaben PET in Patients Incorrectly Diagnosed with Alzheimer's Disease.
Sabbagh MN; Schäuble B; Anand K; Richards D; Murayama S; Akatsu H; Takao M; Rowe CC; Masters CL; Barthel H; Gertz HJ; Peters O; Rasgon N; Jovalekic A; Sabri O; Schulz-Schaeffer WJ; Seibyl J
J Alzheimers Dis; 2017; 56(2):441-446. PubMed ID: 27983552
[TBL] [Abstract][Full Text] [Related]
35. Dissociation of amyloid biomarkers in PET and CSF in Alzheimer's disease: a case report.
Schroeter ML; Tiepolt S; Marschhauser A; Thöne-Otto A; Hoffmann KT; Barthel H; Obrig H; Sabri O
BMC Neurol; 2015 Aug; 15():152. PubMed ID: 26303364
[TBL] [Abstract][Full Text] [Related]
36. Potential Clinical Value of Multiparametric PET in the Prediction of Alzheimer's Disease Progression.
Chen X; Zhou Y; Wang R; Cao H; Reid S; Gao R; Han D;
PLoS One; 2016; 11(5):e0154406. PubMed ID: 27183116
[TBL] [Abstract][Full Text] [Related]
37. Imaging in-vivo tau pathology in Alzheimer's disease with THK5317 PET in a multimodal paradigm.
Chiotis K; Saint-Aubert L; Savitcheva I; Jelic V; Andersen P; Jonasson M; Eriksson J; Lubberink M; Almkvist O; Wall A; Antoni G; Nordberg A
Eur J Nucl Med Mol Imaging; 2016 Aug; 43(9):1686-99. PubMed ID: 26996778
[TBL] [Abstract][Full Text] [Related]
38. The role of epsilon phenotype in brain glucose consumption in Alzheimer's disease.
Ricci M; Chiaravalloti A; Martorana A; Koch G; De Lucia V; Barbagallo G; Schillaci O
Ann Nucl Med; 2020 Apr; 34(4):254-262. PubMed ID: 32016694
[TBL] [Abstract][Full Text] [Related]
39. Modeling grey matter atrophy as a function of time, aging or cognitive decline show different anatomical patterns in Alzheimer's disease.
Dicks E; Vermunt L; van der Flier WM; Visser PJ; Barkhof F; Scheltens P; Tijms BM;
Neuroimage Clin; 2019; 22():101786. PubMed ID: 30921610
[TBL] [Abstract][Full Text] [Related]
40. Feasibility and acceptance of simultaneous amyloid PET/MRI.
Schütz L; Lobsien D; Fritzsch D; Tiepolt S; Werner P; Schroeter ML; Berrouschot J; Saur D; Hesse S; Jochimsen T; Rullmann M; Sattler B; Patt M; Gertz HJ; Villringer A; Claßen J; Hoffmann KT; Sabri O; Barthel H
Eur J Nucl Med Mol Imaging; 2016 Nov; 43(12):2236-2243. PubMed ID: 27435367
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
